Theracryf (LON:TCF – Get Free Report) announced its earnings results on Tuesday. The company reported GBX (0.36) ($0.00) earnings per share for the quarter, Digital Look Earnings reports. Theracryf had a negative net margin of 792.17% and a negative return on equity of 99.97%.
Theracryf Price Performance
Shares of LON:TCF opened at GBX 0.27 ($0.00) on Tuesday. The firm has a market capitalization of £1.29 million, a price-to-earnings ratio of -0.26 and a beta of 1.42. Theracryf has a 12 month low of GBX 0.20 ($0.00) and a 12 month high of GBX 1.25 ($0.02). The business’s 50 day simple moving average is GBX 0.24 and its 200-day simple moving average is GBX 0.48.
Theracryf Company Profile
Formerly Evgen Pharma plc, the Company acquired Chronos Therapeutics in April 2024.
Featured Stories
- Five stocks we like better than Theracryf
- What is a Bond Market Holiday? How to Invest and Trade
- Chewy Stock Gets a New $7.1 Billion Investor and Analyst Upgrade
- Why Are Stock Sectors Important to Successful Investing?
- Ulta’s Beautiful Q1 Earnings Report Points to More Gains Ahead
- Which Wall Street Analysts are the Most Accurate?
- Top 3 ETFs Defense Hawks Are Buying
Receive News & Ratings for Theracryf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theracryf and related companies with MarketBeat.com's FREE daily email newsletter.
